fbpx

Day

May 29, 2017
Ness Ziona, Israel and Chapel Hill, NC –May 23, 2017 – Atox Bio today announced that the Phase 3 ACCUTE study, evaluating Reltecimod (previously AB103) in patients with Necrotizing Soft Tissue Infections, will continue as planned without modification based on the successful completion of a pre-specified futility analysis.  The recommendation was made by the independent...

News

Brain stimulation to relieve symptoms of Parkinson’s disease
25. January 2021
Mini-Brains to shed light on nervous disorders
25. January 2021
Mechanisms of schizophrenia
25. January 2021

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge